Gastric Venous Reconstruction After Total Pancreatectomy
Launched by UNIVERSITY HOSPITAL HEIDELBERG · Apr 14, 2021
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new approach to help patients who are undergoing a total pancreatectomy, which is a surgery to remove the pancreas. Sometimes, during this surgery, doctors have to cut a vein that helps drain blood from the stomach. This can lead to a problem called gastric venous congestion, which can cause serious complications like stomach damage and infection. To prevent these issues, patients often need to have part of their stomach removed, which can greatly affect their quality of life. This study is exploring a technique to reconstruct the blood flow from the stomach so that this extra surgery can be avoided.
To be eligible for the trial, participants should be at least 18 years old and need to give their consent to join. They must be scheduled for an elective total pancreatectomy with splenectomy (removal of the spleen) and have their coronary vein tied off during the surgery. However, those who have had previous pancreas surgery or have other specific complications may not be able to participate. The trial is currently not recruiting participants, but once it starts, those who join can expect to be part of important research aimed at improving outcomes for patients undergoing this type of surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Provide written informed consent
- • Elective total pancreatectomy for malignant or benign pancreatic lesions or chronic pancreatitis with splenectomy
- • Intraoperative ligation of coronary vein
- Exclusion Criteria:
- • Gastric resection due to malignant infiltration
- • Non-reconstructable gastric venous drainage
- • Previous pancreas surgery
About University Hospital Heidelberg
University Hospital Heidelberg is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a key player in translational medicine, the hospital integrates cutting-edge scientific discoveries with patient care, facilitating a robust environment for clinical trials. With a diverse range of specialties and a multidisciplinary approach, University Hospital Heidelberg aims to improve therapeutic outcomes and enhance the quality of life for patients through evidence-based practices. The institution is dedicated to fostering collaborations with academic partners, industry stakeholders, and regulatory bodies to drive forward-looking research initiatives and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Heidelberg, , Germany
Heidelberg, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials